{"schema_version":"secwatch.filing_event.v1","accession":"0001588978-26-000020","form_type":"8-K","ticker":"PRCT","cik":"0001588978","company_name":"PROCEPT BioRobotics Corp","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.529697+00:00","generated_at":"2026-05-15T01:56:02.934847+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PROCEPT BioRobotics Reports Q1 2026 Revenue of $83.1M, Up 20% YoY; Net Loss Widens to $31.6M","bullets":["Total revenue $83.1M, +20% YoY; U.S. procedures 12,200, +30% YoY.","Sold 49 U.S. Hydros systems, ASP ~$485,000; U.S. install base 765 systems, +40% YoY.","FDA clearance of second-generation FirstAssist AI software for Aquablation therapy.","Full-year 2026 revenue guidance $390M-$410M, growth 27%-33%; adjusted EBITDA loss outlook $30M-$17M.","Net loss $31.6M vs $24.7M in prior year; adjusted EBITDA loss $18.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001588978-26-000020","json":"https://secwatch.observer/filing/0001588978-26-000020.json","markdown":"https://secwatch.observer/filing/0001588978-26-000020.md","text":"https://secwatch.observer/filing/0001588978-26-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1588978/000158897826000020/0001588978-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1588978/000158897826000020/prct-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T01:56:02.934847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"051430382391b773effae1c71a00483bdb20801d","claim":"PROCEPT BioRobotics Corp reported the quarter ended March 31, 2026 results: revenue $83.1 million, net income Net loss was $31.6 million. Guidance reaffirmed.","evidence_excerpt":"accountability, and commercial discipline, and our first quarter results reflect the early impact of that work,\" said Larry Wood, Chief Executive Officer. \"We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing.\" Wood continued: “Aquablation® users completed approximately 12,200 U.S. procedures in the first quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1588978/000158897826000020/0001588978-26-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$83.1 million"},{"label":"Net income","value":"Net loss was $31.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}